Extracellular vesicles (EVs) released during cell stress, or demise, can contain a barcode of the cell origin, including specific microRNAs (miRNAs). Here, we tested the hypothesis that during early alcoholic steatohepatitis (ASH) development, hepatocytes (HCs) release EVs with an miRNA signature that can be measured in circulation. A time-course experiment showed that after 2 weeks of intragastric infusion, a time point that results in isolated steatosis, there was no increase of blood EVs. After 4 weeks of infusion, mice developed features of early ASH accompanied by a marked increase in the level of EVs in blood (P < 0.05), as well as in culture media of isolated HCs (P < 0.001) and hepatic macrophages (P < 0.001), with HCs being the predominant source of EVs. The transcriptome analysis of HC-EVs from ASH mice detected differentially expressed miRNAs, including nine significantly up-regulated and four significantly down-regulated miRNAs. Target prediction and pathway analyses of the up-regulated miRNAs identified 121 potential target genes involved in inflammatory and cancer pathways, such as nuclear factor kappa B, EGF, Wnt, and B-cell lymphoma 2. Three miRNAs, let7f, miR-29a, and miR-340, were increased in blood EVs from ASH mice (P < 0.05), but not in blood EVs from three other models of chronic liver injury, including bile duct ligation, nonalcoholic steatohepatitis, and obese mice, as well as EVs released from hepatocytes exposed to ethanol. Blood EV level (P < 0.01) and three miRNAs (P < 0.05) were significantly increased in patients with ambulatory mild ALD as compared to nonalcoholics. Conclusion: Damaged hepatocytes from ASH mice are a key EV source with a specific miRNA cargo, which are specific for ASH-related liver injury. These findings uncover EVs as a potentially novel diagnostic for ASH. (HEPATOLOGY 2017;65:475-490).
A lcoholic liver disease (ALD) is one of the most common forms of chronic liver disease in the United States and many other countries.
(1) ALD represents a wide spectrum of liver damage ranging from alcoholic steatosis, alcoholic steatohepatitis (ASH), to cirrhosis, resulting in liver failure and hepatocellular carcinoma. (2, 3) Accumulating evidence indicates that hepatocyte stress, and eventually hepatocyte death, plays a central role in inflammation and hepatic injury during the progression of ALD. (4) (5) (6) Hepatic macrophages (HMs) are involved in the progression of ethanol (EtOH)-induced liver damage. (7) (8) (9) However, the molecular mechanisms and signaling pathways involved in the cross-talk between stressed, lipid-overloaded hepatocytes (HCs) and HMs in ASH remain poorly understood. Moreover, the identification of a specific signature, or "barcode," from damaged hepatocytes in ASH may help establish mechanistic-based liver-specific and disease-specific biomarkers that may revolutionize the way we diagnose and monitor patients with this condition.
Extracellular vesicles (EVs) are small membrane vesicles released in a highly regulated manner from damaged or activated cells. EVs are categorized as exosomes or microparticles based on size, less than 100 nm or 100-1,000 nm, respectively. Various cells release EVs, which circulate in plasma of healthy humans and act as a natural delivery system under homeostasis. (10) EVs are effective communicators that are generated by a cell of origin or parenteral cell and can act on a number of target cells in the vicinity of the origin in a juxtacrine manner, or at distant sites acting as long-range signals. (11) EV cargo may reflect the cell of origin as well as the specific stress that induces their formation and release. They transport a variety of bioactive molecules, including messenger RNA (mRNA), microRNAs (miRNAs), proteins, and lipids that can be transferred among cells, regulating various cellular responses. (11, 12) Here, we tested the hypothesis that, during ASH development, HCs release EVs with an miRNA signature that can be detected in blood. To address this hypothesis, we have taken an approach to isolate and culture HCs or HMs from C57BL6 mice after 2 and 4 weeks of intragastric continuous EtOH infusion, or pair-fed control diet, and EVs released by the cells were isolated and characterized by flow cytometry, electron microscopy, and dynamic light scattering. miRNA encapsulated in hepatocyte-derived EVs (HC-EVs) was assessed by transcriptome analysis and bioinformatics. miRNA specificity for ASH was investigated using other models of chronic liver injury, cultured hepatocytes exposed to EtOH, and ambulatory patients with ALD.
Materials and Methods

HUMAN SAMPLES
Patients fulfilling the DSM-IV criteria (13) for alcohol dependence and with active alcohol consumption and ALD were compared to individuals without alcohol dependency (weekly alcohol intake of less than 140 g; nonalcoholic controls). Written informed consent was obtained from all patients and controls. Patient characteristics are shown in Table 1 . The study protocol was approved by the Ethics Committee of the Universit e Catholique de Louvain (Brussels, Belgium) by the Human Research Protections Program of the University of California San Diego (La Jolla, CA) and of the VA San Diego Healthcare System (San Diego, CA).
ANIMAL STUDIES
Use and care of the animals was reviewed and approved by the Institutional Animal Care and Use Committee at Southern California University (Los Angeles, CA). The early ASH mouse model using intragastric infusion was generated as described and produced by the Animal Core of the Southern California Research Center for ALPD and Cirrhosis. (14) After a 1-week acclimatization period with infusion of a control high-fat diet, ethanol infusion was initiated at a dose of 22.7 g/kg/day, which was incrementally increased every 2 days until it reached 29.2 g/kg/day from days 9 to 14 and 30.9 g/kg/day from days 15 to 21. At the initial ethanol dose, total caloric intake was set at 533 Cal/kg/day, and the caloric percentages of ethanol, dietary carbohydrate (dextrose), protein (lactalbumin hydrolysate), and fat (corn oil) were 29%, 13%, 23%, and 35%, respectively. Vitamin, salt, and trace mineral mix are included at the recommended amounts by the Committee on Animal Nutrition of the National Research Council (AIN-76A, 4.42 and 15.4 g/L, respectively; Dyets Inc, Bethlehem, PA). Pair-fed control mice received dextrose solution isocaloric to EtOH plus the basal diet. Following 4 weeks of intragastric alcohol feeding, mice were to be sacrificed for analysis (n 5 5 pairs).
LIVER AND BLOOD SAMPLE PREPARATION
A part of liver was collected from the right robe before liver perfusion for HC or HM isolation performed by the Integrative Liver Cell Core of the University of Southern California as described below. A piece of liver tissue was fixed in 10% formalin for 24 hours and embedded in paraffin, incubated in RNAlater Solution (Life Technologies, Carlsbad, CA) for RNA isolation, or frozen in liquid nitrogen and stored in -808C. Blood was collected with or without Abbreviations: C, Caucasian; AA, African American; AI, American Indian; NH, Native Hawaiian; BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
anticoagulant following centrifugation at 12,000 rpm for 15 minutes. Serum or plasma was stored in -808C.
LIVER HISTOLOGY AND IMMUNOSTAINING
Tissue sections (5 lm) were prepared and routinely stained for hematoxylin-eosin (H&E). Immunohistochemistry staining for myeloperoxidase (MPO; Myeloperoxidase Ab-1; Thermo Scientific, Waltham, MA) was performed in formalin-fixed, paraffin-embedded livers, according to the manufacturer's instruction.
REAL-TIME PCR
Total RNA was isolated from liver tissue using RNeasy Tissue Mini kit (Qiagen, Valencia, CA). Reverse transcripts (the complementary DNA [cDNA]) were synthesized from 1lg of total RNA using the iScript cDNA Synthesis kit (Bio-Rad). Realtime polymerase chain reaction (PCR) quantification was performed using SYBR-Green and CFX96 Ther- 
CELL ISOLATION AND CELL CULTURE
Liver cells were collected as described. (15) Briefly, C57BL/6 mouse liver was digested with collagenase perfusion through portal vein and isolated HCs with centrifugation at 50g for 1 minute. HMs were isolated from ASH mice with OptiPrep (Axis-Shield PoC AS, Oslo, Norway) as described (16) for EV production. HepG2 cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco, Camarillo, CA) supplemented with 10% fetal bovine serum (FBS; Cellgro, Manassas, VA), penicillin and streptomycin (Gibco), and sodium pyruvate (Gibco) at 378C in a 10% CO 2 incubator. AML12 cells were maintained in DMEM-12 (Gibco) supplemented with 10% FBS (Cellgro, Manassas), penicillin and streptomycin, insulin-transferrine-selenium (Gibco), and dexamethasone (Roche, Indianapolis, IN) at 378C in a 10% CO 2 incubator.
IMMUNOBLOTTING ANALYSIS
For immunoblotting analysis, 50 lg of isolated HC lysate was resolved by a 4%-20% gradient gel, transferred to a nitrocellulose membrane, and blotted with the appropriate primary antibodies. Membranes were incubated with peroxidase-conjugated secondary antibody (Cell Signaling Technology, Danvers, MA). Protein bands were visualized using an enhanced chemiluminescence reagent and digitized using a charge-coupled device camera (ChemiDoc; Bio-Rad, Hercules, CA). A rabbit anticleaved caspase 3, anticaspase 3, anti-phospho-MYPT1, or anti-MYPT1 was purchased from Cell Signaling Technology, and antibeta actin was purchased from GeneTex (Irvine, CA). Protein load was verified using glyceraldehyde-3-phosphate dehydrogenase (GeneTex), or PORIN (GeneTex) antibody.
CELL-DERIVED OR BLOOD EV ISOLATION
Isolated HCs or HMs from ASH or pair-fed control mice were cultured in medium-2% EV-depleted FBS (SBI, San Diego, CA). Conditioned media of isolated HCs or HMs were collected after 3 or 24 hours of culture (new medium was added after 3-hour collection) and cleared from cell debris by centrifugation at 2,000g for 10 minutes at 108C. Conditioned media of HepG2 or AML12 were collected after 24 hours of culture with 250 mM of EtOH in serum-free growth medium and cleared from cell debris by centrifugation at 2,000g for 10 minutes at 108C. Cellderived EVs from conditioned medium or blood EVs from plasma of 4 weeks of pair-fed control and ASH mice, as well as 10 days of bile duct ligation mice, 20 weeks of nonalcoholic steatohepatitis (NASH) mice, and 12 weeks of obese mice, were isolated by ultracentrifugation at 100,000g for 60 minutes at 108C (Beckman L7-65; Beckman-Coulter, Palo Alto, CA). Pellet (EVs) was resuspended in phosphate-buffered saline and stored at -808C.
MEASUREMENT OF EVs
Conditioned medium or plasma was incubated with Calcein-AM (Life Technologies) for 30 minutes at room temperature. The number of EVs was determined using 2.5-lm Alignflow alignment beads (Life Technologies) as the size standards for flow cytometry, BD LSRII Flow Cytometer System (BD Biosciences, San Jose, CA). Data were analyzed using FlowJo software (TreeStar Inc., Ashland, OR).
EV SIZE DETERMINATION
For dynamic light scattering analysis, entire size was measured by Zetasizer nano ZS90 (Malvern). For transmission electron microscopy, EVs were adhered to 100 mesh Formvar and carbon-coated grids for 5 minutes at room temperature. Grids were washed once with water, stained with 1% uranyl acetate (Ladd Research Industries, Williston, VT) for 1 minute, dried, and viewed using a JEOL 1200 EXII transmission electron microscope. Images were captured using a Gatan Orius 600 digital camera (Gatan, Pleasanton, CA).
QUANTIFICATION OF ENCAPSULATED miRNA LEVELS
Encapsulated miRNAs were extracted using miRNase (Qiagen), according to the manufacturer's instructions. From making template to quantification of miRNAs were performed as described. (15) Briefly, templates were made from 10 ng of total RNA using an miRNA reverse-transcription (RT) kit (Life Technologies) with specific primers, which are provided with TaqMan microRNA probes (Life technologies). Real-time PCR quantification for miRNA expression was performed using a TaqMan miRNA expression assay from Life Technologies. Cq value was converted to relative number using power formulation.
miRNA SEQUENCING
Quality and quantity of purified small RNA was assessed using an Agilent Tapestation and a NanoDrop ND-1000, respectively. Libraries were generated from 100 ng of total RNA, using the TruSeq Small-RNA Sample Prep Kit (Illumina, San Diego, CA), following the manufacturer's instructions. Library quality was assessed using a High Sensitivity DNA kit (Agilent, Santa Clara, CA). Libraries were multiplexed and sequenced at 13 pM to an average depth of 7.5 million reads with 50-base-pair single-end reads on an Illumina HiSeq2500 using V4 chemistry.
SEQUENCING DATA ANALYSIS
The raw sequencing reads in FASTQ format went through preprocessing first to trim 3 0 adapter and next to keep only reads whose length is between 17 and 27 bases. Using bowtie, the survived reads were aligned to reference resources, such as mouse genome, miRNA precursor sequence, and noncoding RNAs, allowing only up to two mismatches. Only the reads mapped to both genome and precursor, but not to small RNAs other than miRNA, were selected for expression-level quantification. Then, miRNA expression counts were quantified, normalized, calculated for fold-change between the treated and control groups, and tested for significance of differential expression using a negativebinomial model. (17) The Benjamini-Hochberg method (18) was applied to adjust for multiple testing on the raw P values of a differential expression test. MAGI, a web service for fast miRNA-seq analysis in a Graphics Processing Unit infrastructure, were used for a pipelined analysis of sequencing data. (19) 
PATHWAY ANALYSIS
The top 13 differentially expressed miRNAs with raw P value less than 0.05 were chosen for pathway enrichment analysis. DIANA-miRPath (20) and inhouse-developed Python scripts were used for pathway analysis. For each miRNA, a set of target genes was created with a threshold of prediction score 0.7 against a micro coding DNA sequence target prediction database. The union set comprising all 13 sets of target gene was mapped to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways to derive significantly enriched pathways using Fisher's exact test. Two heatmaps, miRNA-by-sample and miRNA-by-pathway, were drawn with DIANA-miRPath. Among these, <Pathways In Cancer>, which had 121 genes targeted by eight miRNAs, was selected for visualization. Cytoscape (21) was used to draw an miRNA-gene interaction plot. GeneMANIA (22) was used to infer gene-gene interaction on top of miRNA-gene interaction. Two interaction plots were merged into a single graph.
STATISTICAL ANALYSES
All data are expressed as mean 6 SEM, unless otherwise noted. Data were analyzed using t tests in two groups, ASH mice and pair-fed control mice, and oneway analysis of variance in EV functional assay using GraphPad (GraphPad Software Inc., La Jolla, CA) for comparison of continuous variables. Data were analyzed using Mann-Whitney in two groups, ALD and nonalcoholic (control) human, using GraphPad (GraphPad Software Inc.). Differences were considered to be significant at P 0.05.
Results
ASH IS ASSOCIATED WITH A MARKED INCREASE IN BLOOD EVs
In order to assess the link between changes in blood EV levels with ASH, we used the 4-week intragastric feeding model, which leads to development of mild ASH. The ratio of liver to body weight was significantly higher (P < 0.001) in ASH mice compared to pair-fed control mice (Fig. 1A) . As expected, these mice developed the features of ASH, including significant steatosis and focal inflammation (Fig. 1B) . Focal neutrophil infiltration, assessed by MPO immunohistochemistry of liver sections, was significantly increased (3.5-fold; P < 0.05) in ASH mice compared to pairfed control mice (Fig. 1C) . Markers of proinflammatory M1 polarization were significantly increased in the ASH mice, including TNF-a (P < 0.05) and IL-1 a (P < 0.05), and iNOS (M1 macrophage marker), whereas Arginase 1 (M2 macrophage marker) mRNA level was significantly decreased (P < 0.001) in ASH mice compared to pair-fed control mice (Fig. 1D) . The inflammasome is known to be a key factor in the progression of ALD (23, 24) ; thus, mRNA expression levels of inflammasome-related components were assessed by qPCR. NLRP3, ASC (P < 0.01), procaspase-1 (P < 0.05), and pro-IL-1b were upregulated in ASH mice compared to pair-fed control mice (Fig. 1D) , although NLRP3 and pro-IL-1b did not reach statistical significance. Having documented the various histological and molecular features of early ASH, we then assessed whether these features were associated with changes in levels of EVs in circulation. Stained blood EVs had a distinct peak, with 10-fold intensity, compared to unstained blood EVs by flow cytometry analysis (Fig. 1E) . Quantification showed that the number of blood EVs was no different after 2 weeks between EtOH and pair-fed control mice, whereas it was significantly increased (P < 0.05) in ASH mice at 4 weeks (Fig. 1E) . Characterization of blood EVs by dynamic light scattering (Fig. 1F ) and electron microscopy ( Fig. 1F) identified two subpopulations of EVs: exosomes and microparticles.
HCs ARE THE MAJOR SOURCE OF EV RELEASE IN THE ASH LIVER
We expected that injured HCs are the major site of EV release from two lines of evidence: (1) Cultured HCs exposed to various stressors, such as free fatty acid, cytokines, or alcohol, release EVs (25, 26) and (2) encapsulated miR-122/192 or asialoglycoproteinreceptor, which is abundant in the HCs, is detected in blood EVs or miRNAs. (27, 28) However, there is no direct evidence that damaged HCs release EVs in liver disease. To address this question, we isolated primary HCs from ASH or pair-fed control mice with cell viability of 90.5% or 94.5%, respectively (Supporting Fig.  S1 ), cultured the HCs, and assessed the HC-EVs. We also investigated hepatic-macrophage-derived EVs (HM-EVs) to determine the quantitative comparison for EV release by these two cell types in liver from ASH mice. Conditioned medium containing HCEVs or HM-EVs was collected after 3 hours of culture, replenished with fresh medium and collected at 24 hours, without any stimulus ( Fig. 2A) . After removing cell debris carefully with low-speed centrifugation, HC-EVs or HM-EVs were stained with calcein and analyzed using flow cytometry. The intensity of stained HC-EVs was 10-fold higher than unstained HC-EVs (Fig. 2B) . The pattern of the calcein-positive population was the same between HC-EVs from ASH or control samples (Fig. 2C) . The number of HC-EVs and HM-EVs from ASH were significantly increased 
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compared to HC-EVs and HM-EVs from pair-fed control animals (P < 0.001; Fig. 2D ). Furthermore, the number of HC-EVs was 10 times higher than HM-EVs in ASH mice, demonstrating that HCs are the key EV producer (Fig. 2D ). HC-EV or HM-EV morphology appeared the same when assessed by electron microscopy (Fig. 2E) . As shown for EV release during lipotoxicity and ethanol exposure, (25, 26, 29) we found that release of EVs by HCs from ASH mice was associated with increases in cleaved caspase 3 and phospholated myosin phosphatase target subunit 1 (MYPT1) in HCs, suggesting that activation of caspases and pho-kinase pathways are also playing a role in their release ( Fig. 2F and Supporting Fig. S2 ).
DIFFERENTIALLY EXPRESSED miRNAs
Circulating miRNAs encapsulated in EVs are known to be potentially novel biomarkers in alcoholic hepatitis.
(30) Therefore, we further investigated whether encapsulated miRNAs in HC-EVs could provide a "barcode" to distinguish ASH from control animals using the miRNA transcriptome. A total of 147 known miRNAs were quantified by alignment with at least one read in either group, and we found 70 upregulated miRNAs and 73 down-regulated miRNAs in ASH HC-EVs compared to miRNAs in control HC-EVs. Four miRNAs (miR-690, -673-5p, -540-5p, and -540-3p) were detected only in ASH HCEVs (Supporting Table S1 ). Alternatively, 13 miRNAs were significantly up-or down-regulated in ASH HC-EVs compared to control HC-EVs (P < 0.05; Fig. 3A) . Whereas miR-122 was the most abundantly expressed, commensurate with previous findings, (31) there was no significant difference between HC-EVs from ASH mice and the control group (data not shown). Let-7f showed the highest expression level among the 13 top differentially expressed miRNAs (Fig. 3B) . miR-34a, which is known to play a role in hepatic metabolic disease, showed significantly higher expression in ASH samples. (32) The heatmap of miRNAs expression (Fig. 3C) showed high within-group similarity and low between-group similarity among 13 different miRNA expression profiles.
TARGET INTERACTOME OF SIGNIFICANTLY UP-REGULATED miRNAs IN HC-EVs FROM ASH
A heatmap of miR by pathway is drawn in Fig. 4A . The row enlists eight top differentially expressed miRNAs, and the column contains 33 enriched KEGG pathways. Cancer, transcriptional misregulation in cancer, and the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway are highly regulated by eight miRNAs. Eight of the nine significantly up-regulated miRNAs in ASH HC-EVs were involved in inflammatory and cancer pathways with 121 potential target genes, including nuclear factor kappa B (NF-jB), Jun, IL-6, phosphatase and tensin homolog (Pten), small mothers against decapentaplegic (smad), epidermal growth factor, Wnt, and B-cell lymphoma 2 (Bcl2; Fig. 4B ; Supporting Table S2 ). Whereas miR-340-5p had the most target genes (n 5 54), miR-541-5p had the least target genes (n 5 4). Interestingly, Runx1t1 was targeted by four miRNAs: miR-29a-3p, miR-340-5p, miR-541-5p, and let-7f-5p. In addition, six genes (Pten, Pdgfra, Mapk9, Lamc1, Igf1, and Arf) were targeted by three miRNAs; specifically, let7f-5p, miR-29a-3p, -340-5p, -34a-5p, and -3473 shared the majority of target genes (Fig. 4B) . Figure 4C 
miRNA BARCODE DERIVED FROM HC-EVs CAN BE USED TO IDENTIFY ASH USING BLOOD EVs
The demonstration that HC-EVs from ASH mice carry a specific miRNA barcode led us to the hypothesis that the miRNA profile present in EVs released by damaged hepatocytes during ASH may be used in blood EVs to noninvasively identify the presence of ASH. To address this question, we purified blood EVs from ASH or pair-fed control mice, extracted the RNA, and performed a qPCR analysis to determine expression level of seven miRNAs derived from ASH HC-EVs (Fig. 5A) . From the seven miRNAs tested, three allowed for efficient discrimination between ASH and pair-fed control mice, including Let-7f-5p and miR-29a-3p, the levels of which were significantly up-regulated in ASH blood EVs compare to control blood EVs (P < 0.05; Fig. 5B ), as well as miR-340-5p that was only detected in ASH blood EVs (Fig. 5B) . miR-3473b levels were similar in blood EVs from both ASH and pair-fed mice whereas the other miRNAs, including miR-34a, -541, -143-, and -1195 levels, were below the detectable range in blood EVs by qPCR (data not shown).
miRNA BARCODE IS SPECIFIC FOR ALCOHOLIC LIVER INJURY AND PRESENT IN HUMAN ALCOHOLIC PATIENTS
To assess the specificity of the identified miRNA barcode in ASH mice, we assessed three miRNAs (let7f, miR-29a, and miR340) in blood EVs from different liver disease mouse models, including bile duct ligation (BDL), NASH, and obese mice (Fig. 5A) . Three miRNAs were below the detectable range in blood EVs from BDL and NASH mice and were expressed at low levels in blood EVs from obese mice by qPCR (Fig. 5B) . In order to further explore whether the miRNA barcode identified reflects alcohol exposure, we treated HCs with EtOH and assessed miRNA level in HC-EVs in vitro. As shown, (25) release of HC-EVs were significantly increased in HepG2 and AML12 treated with 250 mM of EtOH (P < 0.05; Fig. 5C,D) ; however, three miRNA levels in HepG2-or AML12-derived EVs were not increased, except miR-340 in AML12-derived EVs ( Fig. 5C,D) . These results strongly suggest that the identified miRNA profile is a specific marker of ALDrelated liver injury. Finally, in order to address the potential translational significance of our findings for patients with ALD, we conducted an early-phase pilot study where we quantified three miRNA levels in blood EVs from a small group of ambulatory patients with ALD versus individuals without alcohol dependency (nonalcoholics). Blood EVs were stained with calcein and analyzed using flow cytometry. Intensity of stained blood EVs was higher than unstained blood EVs (Fig. 6A ). Blood EVs were significantly increased in patients with ALD compared to nonalcoholics (P < 0.01; Fig. 6A ). Similar findings were observed for the three miRNAs in blood EVs (let-7f, P < 0.05; miR29a, P < 0.05; miR-340, P < 0.05; Fig. 6B ).
Discussion
The key finding of this study is the demonstration that, in experimental ASH mice, there is an increased production and release of EVs, predominantly by HCs, that contain an miRNA signature detectable in blood EVs as a barcode to identify ASH. ALD is a wide-spectrum disease that includes steatosis, steatohepatitis, or ASH and, in severe cases, fibrosis and/or cirrhosis. Steatosis, characterized by fat accumulation in HCs, is, by far, the most common form of ALD and tends to follow a benign clinical course that resolves upon cessation of alcohol consumption. (33, 34) A subgroup of patients with ALD progress to ASH, which is characterized by the persistence of fatty liver accompanied by a robust inflammatory response. In later stages of ALD, collagen deposition and regenerative nodules can result in development of fibrosis and cirrhosis, respectively. Although much progress has been made in the understanding of the mechanisms by which alcohol damages the liver, there is still currently a paucity of pharmacological strategies to stop, or reverse, disease progression. One of the key factors limiting the development of effective therapies is the lack of reliable, mechanism-based noninvasive biomarkers that can help identify patients at risk for disease progression. In the current study, we set out to test the hypothesis that, during ASH development, fat-laden HCs release EVs with an miRNA signature that can be measured in circulation. In order to do this, we developed various novel experimental approaches that allowed us to directly test our hypothesis. Recent studies from our lab, as well as others, have demonstrated that the number of blood EVs increases in murine models of nonalcoholic and alcoholic liver disease. (28, 30) whereas in vitro exposure of primary rat HCs to saturated fatty acids, (26) or Huh7.5 or HepG2 cells to ethanol, (25, 29) results in release of EVs into media. The current study builds on these findings and demonstrates that both exosomes and microparticles are increased in circulation of mice with ASH induced by continuous intragastric ethanol feeding. Moreover, we were able to demonstrate, for the first time, that both HCs and HMs isolated from this mouse model produce large quantities of EVs and that HCs are the major source for EV release in the ASH liver. Data from our lab, as well as others, have previously showed that EVs are efficiently internalized into target cells and the transferring of their composition, such as proteins, lipids, or miRNAs, is a key mechanism by which EVs modulate cell signaling in target cells. (12, 13, 35) miRNAs have an especially crucial role in gene regulation, with the majority of miRNAs binding to the 3 0 untranslated region of the target mRNA leading to translational suppression, and some miRNAs bind to their target mRNA with a perfect match, resulting in gene suppression through mRNA cleavage. (14) Indeed, we and others have recently shown an inverse correlation between expression levels of certain miRNAs in the liver and those in blood EVs, or plasma, suggesting the potential for using specific miRNAs as sensitive and informative biomarkers of liver damage. (15) (16) (17) (18) (19) (20) There are mainly two forms of circulating miRNAs: encapsulated miRNAs in EVs (EV-miRNAs) and complex miRNA with noncoding RNA binding proteins known as Argonaute proteins (Ago-miRNA). (21) Ago-miRNA cannot integrate into recipient cells because of its size and lack of bioactivity for penetration, (22) whereas EV-miRNAs can efficiently penetrate recipient cells with their miRNAs. (23) Our analysis identified 13 significantly up-or down-regulated miRNAs in ASH HC-EVs compared to control HC-EVs. Eight miRNAs from the nine significantly upregulated in ASH HC-EVs (miR-541, miR-3473, miR-143, miR-29a, let-7f, miR-340, miR-34a, and miR-3473b) were involved in inflammatory and cancer pathways and potentially regulate 121 target genes, including Bcl2, Jun, IL-6, Pten, smad, and Wnt families. 35, 36 Furthermore, miR34a has been found to play an important role in liver damage and remodeling during ALD with both Caspase-2 and Sirtuin 1 being direct targets of this miRNA. (38) Development of noninvasive reliable biomarkers that allow an assessment of the severity of ALD in patients is greatly needed. Our finding that EVs derived from HCs from ASH mice elucidated a profile of differentially expressed miRNAs, in conjunction with the increased level of EVs in blood, led us to explore the possibility that an miRNA signature can be measured in circulation and exploited for diagnostic purposes. Indeed, we found that three of seven miRNAs tested allowed for efficient discrimination between ASH and pair-fed control mice and between ASH and other causes of liver injury, including cholestatic and metabolic, demonstrating the specificity of the miRNA profile identified. In addition, a shortterm 2-week course of gastric infusion, a time point that is associated with only minimal changes in the liver, did not result in an increase in circulating EVs, although consistent with previous studies. (25, 29) In vitro, exposure of HCs to EtOH did enhance EV release; however, when we explored the miRNA profile, we found that this treatment did not mimic the one found in HCs from ASH mice and in blood from these mice. Taken together, these results suggest that quantitation of EV release and the miRNA barcode are markers for ALD-related liver injury that allows for distinction between ASH and fatty liver and is not a mere consequence of EtOH exposure. We further tested the translational significance of our findings in a pilot small human study consistent of a group of patients with ambulatory ALD and nonalcoholics (controls). This cohort was selected because our intragastric model is a model of early chronic ASH. Previous reports suggested that blood exosomes or EVs are increased in hospitalized patients with acute alcoholic hepatitis. (29, 30) We observed a significant increase in blood EVs in patients with ambulatory ALD. We further found that our identified profile of three miRNAs (let-7f, miR-29, and miR-340) was significantly increased in these patients compared to nonalcoholics. These data hold the promise that this approach may allow for the creation of a customized miRNA array that would serve as a barcode to identify ASH, and future larger, prospective studies in humans are warranted.
In summary, the current study demonstrates, in an established murine model of mild ASH, that EVs are increased in circulation, with HCs being the key source of these EVs, and carry a specific miRNA cargo. These findings uncover EVs as potential novel biomarkers and therapeutic targets for ASH.
